Fremont, California
Boehringer Ingelheim’s Fremont, California facility in the San Francisco Bay Area is the company’s only US biopharmaceutical manufacturing site. Established in 2011 and expanded in 2018, the facility is dedicated to the manufacture of monoclonal antibody medicines and other proteins from mammalian cell culture technology.
The 300,000 square-foot facility features two trains with flexible commercial cell culture capacities, allowing for the simultaneous production of different large-scale products. A third train utilizing disposables is ideally suited for early clinical projects. A center of excellence for continuous manufacturing and perfusion technologies, the site offers additional value for early clinical stage projects.
Related Content
Sites Around the World
Ingelheim
The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany. It is the largest site, producing all new active ingredients and medications during the market launch.
Read more
Sites Around the World
Biberach
The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany. This site is also the largest site in Europe for biopharmaceutical manufacturing.
Read more
Sites Around the World
Vienna
Vienna, Austria, is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Read more